https://www.selleckchem.com/pr....oducts/brm-brg1-atp-
Omission of axillary lymph node dissection (ALND) is accepted for patients with one or two positive sentinel nodes, and studies are focusing on clinically node-positive patients who have been downstaged with neoadjuvant chemotherapy (NAC). Evidence is lacking for patients with positive nodes who undergo surgery upfront. These patients are assumed to have a higher burden of nodal disease such that ALND remains the standard of care. Patients who underwent ALND for breast cancer between 2010 and 2019 at the authors' instit
Curtir
Comentario
Compartilhar
